Literature DB >> 26344214

Rodent Models of Amyotrophic Lateral Sclerosis.

Thomas Philips1, Jeffrey D Rothstein1.   

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease affecting upper and lower motor neurons in the central nervous system. Patients with ALS develop extensive muscle wasting and atrophy leading to paralysis and death 3 to 5 years after disease onset. The condition may be familial (fALS 10%) or sporadic ALS (sALS, 90%). The large majority of fALS cases are due to genetic mutations in the Superoxide dismutase 1 gene (SOD1, 15% of fALS) and repeat nucleotide expansions in the gene encoding C9ORF72 (∼ 40% to 50% of fALS and ∼ 10% of sALS). Studies suggest that ALS is mediated through aberrant protein homeostasis (i.e., ER stress and autophagy) and/or changes in RNA processing (as in all non-SOD1-mediated ALS). In all of these cases, animal models suggest that the disorder is mediated non-cell autonomously, i.e., not only motor neurons are involved, but glial cells including microglia, astrocytes, and oligodendrocytes, and other neuronal subpopulations are also implicated in the pathogenesis. Provided in this unit is a review of ALS rodent models, including discussion of their relative advantages and disadvantages. Emphasis is placed on correlating the model phenotype with the human condition and the utility of the model for defining the disease process. Information is also presented on RNA processing studies in ALS research, with particular emphasis on the newest ALS rodent models.
Copyright © 2013 John Wiley & Sons, Inc. All rights reserved.

Entities:  

Keywords:  Amyotrophic Lateral Sclerosis; RNA processing alterations; aberrant protein homeostasis; glia; motor neuron; rodent models

Mesh:

Substances:

Year:  2015        PMID: 26344214      PMCID: PMC4562058          DOI: 10.1002/0471141755.ph0567s69

Source DB:  PubMed          Journal:  Curr Protoc Pharmacol        ISSN: 1934-8282


  108 in total

1.  A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.

Authors:  R G Miller; J H Petajan; W W Bryan; C Armon; R J Barohn; J C Goodpasture; R J Hoagland; G J Parry; M A Ross; S C Stromatt
Journal:  Ann Neurol       Date:  1996-02       Impact factor: 10.422

2.  An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria.

Authors:  P C Wong; C A Pardo; D R Borchelt; M K Lee; N G Copeland; N A Jenkins; S S Sisodia; D W Cleveland; D L Price
Journal:  Neuron       Date:  1995-06       Impact factor: 17.173

3.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

Authors:  D R Rosen
Journal:  Nature       Date:  1993-07-22       Impact factor: 49.962

4.  Colocalization of NOS and SOD1 in neurofilament accumulation within motor neurons of amyotrophic lateral sclerosis: an immunohistochemical study.

Authors:  S M Chou; H S Wang; K Komai
Journal:  J Chem Neuroanat       Date:  1996-06       Impact factor: 3.052

5.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.

Authors:  G Bensimon; L Lacomblez; V Meininger
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

6.  Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis.

Authors:  M C Dal Canto; M E Gurney
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

7.  Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis.

Authors:  J D Rothstein; L J Martin; R W Kuncl
Journal:  N Engl J Med       Date:  1992-05-28       Impact factor: 91.245

8.  Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis.

Authors:  M E Ripps; G W Huntley; P R Hof; J H Morrison; J W Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

9.  Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis.

Authors:  D Nagy; T Kato; P D Kushner
Journal:  J Neurosci Res       Date:  1994-06-15       Impact factor: 4.164

10.  Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues.

Authors:  K L Taneja; M McCurrach; M Schalling; D Housman; R H Singer
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more
  78 in total

1.  Cortical astroglia undergo transcriptomic dysregulation in the G93A SOD1 ALS mouse model.

Authors:  Sean J Miller; Jenna C Glatzer; Yi-Chun Hsieh; Jeffrey D Rothstein
Journal:  J Neurogenet       Date:  2018-11-06       Impact factor: 1.250

2.  Functional up-regulation of the M-current by retigabine contrasts hyperexcitability and excitotoxicity on rat hypoglossal motoneurons.

Authors:  Filippo Ghezzi; Laura Monni; Andrea Nistri
Journal:  J Physiol       Date:  2018-05-30       Impact factor: 5.182

3.  Characterization of the Mitochondrial Aerobic Metabolism in the Pre- and Perisynaptic Districts of the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Silvia Ravera; Tiziana Bonifacino; Martina Bartolucci; Marco Milanese; Elena Gallia; Francesca Provenzano; Katia Cortese; Isabella Panfoli; Giambattista Bonanno
Journal:  Mol Neurobiol       Date:  2018-04-14       Impact factor: 5.590

4.  The UPR-PERK pathway is not a promising therapeutic target for mutant SOD1-induced ALS.

Authors:  Yulia Dzhashiashvili; Chase P Monckton; Harini S Shah; Rejani B Kunjamma; Brian Popko
Journal:  Neurobiol Dis       Date:  2019-03-26       Impact factor: 5.996

5.  Disruption of calcitonin gene-related peptide signaling accelerates muscle denervation and dampens cytotoxic neuroinflammation in SOD1 mutant mice.

Authors:  Cornelia Ringer; Sarah Tune; Mirjam A Bertoune; Hans Schwarzbach; Kazutake Tsujikawa; Eberhard Weihe; Burkhard Schütz
Journal:  Cell Mol Life Sci       Date:  2016-08-23       Impact factor: 9.261

6.  RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43.

Authors:  Jacob R Mann; Amanda M Gleixner; Jocelyn C Mauna; Edward Gomes; Michael R DeChellis-Marks; Patrick G Needham; Katie E Copley; Bryan Hurtle; Bede Portz; Noah J Pyles; Lin Guo; Christopher B Calder; Zachary P Wills; Udai B Pandey; Julia K Kofler; Jeffrey L Brodsky; Amantha Thathiah; James Shorter; Christopher J Donnelly
Journal:  Neuron       Date:  2019-02-27       Impact factor: 17.173

7.  Macrophage-mediated inflammation and glial response in the skeletal muscle of a rat model of familial amyotrophic lateral sclerosis (ALS).

Authors:  Jonathan M Van Dyke; Ivy M Smit-Oistad; Corey Macrander; Dan Krakora; Michael G Meyer; Masatoshi Suzuki
Journal:  Exp Neurol       Date:  2016-01-13       Impact factor: 5.330

8.  An amyotrophic lateral sclerosis-linked mutation in GLE1 alters the cellular pool of human Gle1 functional isoforms.

Authors:  Laura Glass; T Renee Dawson; Susan R Wente
Journal:  Adv Biol Regul       Date:  2015-11-11

9.  Mutant PFN1 causes ALS phenotypes and progressive motor neuron degeneration in mice by a gain of toxicity.

Authors:  Chunxing Yang; Eric W Danielson; Tao Qiao; Jake Metterville; Robert H Brown; John E Landers; Zuoshang Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-28       Impact factor: 11.205

Review 10.  Dysregulated mitochondrial Ca2+ and ROS signaling in skeletal muscle of ALS mouse model.

Authors:  Jingsong Zhou; Ang Li; Xuejun Li; Jianxun Yi
Journal:  Arch Biochem Biophys       Date:  2019-01-22       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.